title: Immunotherapy in Endometrial Cancer: In the Nick of Time.
abstract: Immunotherapy with checkpoint inhibitors is changing the face of oncology treatments for many tumors, and endometrial carcinoma may not be an exception. Several endometrial cancer groups from the molecular taxonomy are characterized by having an ultramutated/hypermutated genome, which could be the first Achilles' heel identified in this malignancy in decades. Clin Cancer Res; 22(23); 5623-5. ©2016 AACRSee related article by Santin et al., p. 5682.
authors.affiliation: Department of Medical Oncology, Institut Català d'Oncologia-IDIBELL, Barcelona, Spain. jmpiulats@iconcologia.net.
authors.forename: Josep Maria
authors.initials: JM
authors.lastname: Piulats
authors.affiliation: Department of Pathology, Hospital Universitari de Bellvitge-IDIBELL, Barcelona, Spain.|Department of Pathology, Hospital Universitari Arnau de Vilanova, Universitat de Lleida, IRBLLEIDA, Lleida, Spain.
authors.forename: Xavier
authors.initials: X
authors.lastname: Matias-Guiu
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000628:therapy*; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents